As shown in Figure 1, visfatin chemerin, resisitin and SeP aggravate NAFLD through multiple pathways including the activation of receptors (TLR4/CD14), the regulation of transcription factors ((NF-κB) and the release of inflammatory or profibrotic cytokines (TNF-α/IL-6, respectively TGF-β) (98, 99, 104, 123, 124, 126, 132, 150, 154–156). Here, SELENOP is linked to metabolic dysfunction-associated steatotic liver disease.